| Literature DB >> 31433584 |
Eun Young Ki1, Eun Kyung Park1, In Cheol Jeong1, Sung Eun Bak1, Hye Sung Hwang1, Yoo Hyun Chung1, Min Jong Song2.
Abstract
PURPOSE: The aim of this study was to evaluate the feasibility and safety of laparoendoscopic single site (LESS) surgery using an angiocatheter needle in patients with huge ovarian cysts (diameter ≥15 cm).Entities:
Keywords: Huge ovarian cyst; LESS surgery; feasibility; safety
Mesh:
Year: 2019 PMID: 31433584 PMCID: PMC6704019 DOI: 10.3349/ymj.2019.60.9.864
Source DB: PubMed Journal: Yonsei Med J ISSN: 0513-5796 Impact factor: 2.759
Fig. 1Technique of laparoendoscopic single-site (LESS) surgery using an angiocatheter needle for extremely huge ovarian cysts. (A) A large ovarian cyst through a vertical 1.5- to 2.0-cm incision in the umbilical area is shown. (B) An angiocatheter needle connected to a suction line is used to puncture the cyst and aspirate the cyst contents. (C) After cystic contents are aspirated, both ends of the cyst wall are clamped using Kelly clamps. A 5-mm suction tip is inserted after the incision in the puncture hole is extended. (D) After complete suction, the puncture hole of the cyst is closed by purse string suture with 2-0 Vicryl to prevent spillage during LESS surgery. (E) The decompressed ovarian cyst is shown through a Glove port in the intraabdominal cavity. (F and G) After LESS cystectomy or adnexectomy, a huge ovarian tissue is extracorporeally removed by knife-in-bag morcellation through the umbilicus. (H and I) Upon discovery of borderline or malignant tumor in a frozen section, the patient underwent surgical staging.
Characteristics of the Study Subjects (n=31)
| Characteristics | Values |
|---|---|
| Age (yr) | 39 (15–82) |
| Parity | |
| Nulliparous | 18 (58.0) |
| Parous | 13 (42.0) |
| Menopause | |
| No | 22 (71.0) |
| Yes | 9 (29.0) |
| Preoperative mass size (cm) | 18.5 (15.0–30.0) |
| Symptom and sign | |
| Asymptomatic | 3 (9.7) |
| Indigestion | 1 (3.2) |
| Abdominal distension | 1 (3.2) |
| Abdominal discomfort | 2 (6.5) |
| Abdominal palpable mass | 14 (45.1) |
| Abdominal pain | 5 (16.1) |
| Vaginal bleeding | 1 (3.2) |
| Menstrual disorder | 2 (6.5) |
| Urinary symptom | 2 (6.5) |
| CA125 (IU/mL) | 28.6 (6.7–175.0) |
| CA19-9 (IU/mL) | 14.4 (0.7–282.3) |
| BMI (kg/m2) | 24.3 (17.2–37.5) |
BMI, body mass index.
Values are presented as n (%) or median (range) unless otherwise indicated.
Final Pathological Diagnosis of the Study Subjects (n=31)
| Pathological diagnosis | Values |
|---|---|
| Benign | |
| Mucinous cystadenoma | 10 (32.2) |
| Serous cystadenoma | 3 (9.6) |
| Mature cystic teratoma | 4 (12.9) |
| Endometrioma | 2 (6.5) |
| Borderline malignancy | |
| Mucinous borderline malignant tumor | 5 (16.1) |
| Serous borderline malignant tumor | 2 (6.5) |
| Malignancy | |
| Clear cell carcinoma | 1 (3.2) |
| Mucinous cystadenocarcinoma | 2 (6.5) |
| Immature teratoma | 2 (6.5) |
Values are presented as n (%).
Surgical Outcomes (n=31)
| Outcomes | Values |
|---|---|
| Scheduled surgery | |
| Scheduled | 29 (93.5) |
| Emergency | 2 (6.5) |
| Surgical procedure | |
| Unilateral salpingo-oophorectomy | 9 (29.0) |
| Unilateral ovarian cystectomy | 7 (22.6) |
| Bilateral salpingo-oophorectomy | 5 (16.1) |
| Bilateral ovarian cystectomy | 2 (6.5) |
| Unilateral oophorectomy | 1 (3.2) |
| Fertility sparing cytoreductive surgery | 3 (9.7) |
| Laparoscopic surgical staging for borderline malignant tumor | 1 (3.2) |
| Laparoscopic surgical staging for ovarian cancer | 2 (6.5) |
| Conversion to laparotomy | 1 (3.2) |
| Operation time (min) | 150 (80–520) |
| Estimated blood loss (mL) | 100 (20–800) |
| Spillage of cystic content | |
| No | 30 (96.8) |
| Yes | 1 (3.2) |
| Decreased Hb (g/dL) | 2 (0.1–4.1) |
| Postoperative hospital stay (days) | 3 (2–22) |
| Report of frozen biopsy | |
| Benign | 21 (67.7) |
| Borderline malignancy | 7 (22.6) |
| Malignancy | 3 (9.7) |
| Results of final pathological diagnosis | |
| Benign | 19 (61.3) |
| Borderline malignancy | 7 (22.6) |
| Malignancy | 5 (16.1) |
| Use of additional port | |
| Yes | 0 (0.0) |
| No | 31 (100.0) |
| Follow-up periods (mon) | 22 (4–60) |
| Postoperative/perioperative complication | 0 (0.0) |
Hb, hemoglobin.
Values are presented as n (%) or median (range) unless otherwise indicated.
Comparison of Surgical Outcomes among Previous Studies
| Number of study subjects (n) | Tumor size, mean (range) (cm) | Surgical method | Cyst spillage (n, %) | Conversion (n, %) | |
|---|---|---|---|---|---|
| Yi | 3 | 23.1 (13.9–34.0) | Combination† | 0 (0.0) | 0 (0.0) |
| Kim, et al. | 22 | 11.9 (11.6–20.0) | Combination | 2 (9.1) | 1 (4.5) |
| Lee, et al. | 12 | 18 (15–30) | Multiport laparoscopy | ||
| Hong, et al. | 52 | 17 (15–40) | Multiport laparoscopy | ||
| Moulton, et al. | 322 | 6.4 (4.3–8.7) | LESS surgery | 22 (6.8) | |
| Takeda, et al. | 35 | 17.7 (8.8–42.4) | LESS surgery | ||
| Sagiv, et al. | 21 | 2844 (10000–11000) mL* | |||
| Vizza, et al. | 25 | 26 (15–60) | Open laparoscopy | 1 (4.0) | 0 (0) |
| Vlahos, et al. | 53 | 8.4 (7–15) | Multiport laparoscopy | 0 (0) | 0 (0) |
| Song, et al. | 21 | 21.1 (15.9–29.3) | Combination | 2 (9.5) | 1 (4.7) |
| This study | 31 | 18.5 (15–30) | LESS surgery | 1 (3.2) | 1 (3.2) |
LESS, laparoendoscopic single site.
*Tumor volume (mL); †Combined with extracorporeal surgery and laparoendoscopic single-site surgery.